Paradromics Inc. announced on 26 August 2026 that the US Food and Drug Administration has issued an approval letter expanding the types of computing devices that may be used with the company’s investigational Connexus brain-computer interface inside the Connect-One Early Feasibility Study. Compatible personal, internet-connected devices (laptops, tablets, and phones) can now be added to the study without Paradromics needing to seek FDA approval for each new device.
Paradromics is an Austin, Texas-based intracortical BCI operator with roughly 100 employees. The CEO and founder is Matt Angle, PhD. The Chief Clinical Officer is William J. Marks Jr., MD, MS-HCM.
What FDA approved
The prior study scope permitted the Connexus BCI to work with a company-provided computing environment. The 26 August 2026 FDA approval letter expands that scope to compatible personal, internet-connected devices. The category names given in the release are laptops, tablets, and phones. The approval mechanism (IDE supplement, amendment, or a separate approval letter) is not specified in the release. Paradromics’ own wording is “approval letter.”
Once qualified, additional personal devices can be added into the study through Paradromics’ deployment and testing process without a per-device FDA approval. Paradromics calls the user-facing software layer that translates decoded neural intent into communication and computer control Convey.
The Connect-One feasibility study
Connect-One is Paradromics’ FDA-approved Early Feasibility Study of the Connexus BCI, evaluating the system’s ability to safely restore communication and enable computer-device control. Prior US media coverage (Bloomberg, STAT, Wired, as compiled on Paradromics’ press page) dates the original Connect-One IDE clearance to 20 November 2025.
Per Citeline Insight’s 26 August 2026 coverage, Paradromics has identified a second patient for the feasibility study and the first patient has progressed to the closed-loop stage. The second patient’s identity, indication, site, and implantation date have not been disclosed.
A photo in Citeline’s coverage credits Michigan Medicine (Carrie Pitzer) for an intraoperative image of Dr Kurtis Nishimura of Paradromics collecting neural data. The image credit is the strongest publicly readable indication that Michigan Medicine is a Connect-One clinical site, though Paradromics has not explicitly named the site in the announcement.
The Connexus device
Connexus is an implantable intracortical BCI. Paradromics positions it in its own materials as the world’s highest-data-rate BCI. Connexus remains investigational, limited by US law to research use, and has not received marketing authorisation.
The channel count, electrode-array specifications, and full technical architecture are not restated in the 26 August 2026 release.
Where Paradromics sits in the US commercial BCI cohort
Paradromics sits in the US intracortical BCI category alongside Neuralink and Blackrock Neurotech. Synchron sits in the semi-invasive endovascular category. Motif Neurotech operates on the therapeutic-stimulation axis alongside Medtronic, Abbott, Boston Scientific, and NeuroPace. Non-invasive optical operators such as Kernel, and epicortical surface-electrode operators such as Precision Neuroscience and ABILITY Neurotech, sit in different categories.
Neuralink’s PRIME cohort has demonstrated personal-computer control in public and video coverage. The Paradromics approval formalises the same personal-device use case for the Connect-One protocol without requiring a per-device FDA approval.
Where this sits in the broader arc
The 26 August 2026 approval lands in the same August 2026 window as several other US commercial BCI activity signals InsideBCI has covered: DARPA SHINE Special Notice (11 August), DARPA Firefox programme (20 August), ABILITY Neurotech’s Munich intraoperative trial (22 August), the Ackman Oxman Institute announcement (22 August, which named Paradromics’ peer set including Neuralink, Precision Neuroscience, Synchron, Science Corp, and Nudge as illustrative BCI field examples), and Türkiye’s NOROM admission to NATO DIANA (24 August). US federal, US commercial, US philanthropic, and NATO-alliance neurotechnology activities are all moving inside the same window.
Not disclosed
The exact FDA regulatory mechanism used for the expansion (IDE supplement, IDE amendment, or standalone approval letter) is not specified. The second patient’s identity, indication, site, and implantation date are not disclosed. Enrolment cap and enrolment pace for Connect-One are not restated. First-patient closed-loop performance metrics (bit-rate, task accuracy, time-to-independent-use) are not disclosed in the release. Named clinical sites beyond the implied Michigan Medicine attribution are not confirmed. Paradromics’ most recent funding round and cumulative capital raised are not restated in this release.
What to watch
Watch whether Paradromics discloses the second-patient implantation date and site in the coming weeks. Movement from “identified” to “implanted” is the next operational milestone.
Watch whether the first patient’s closed-loop performance is quantified in a peer-reviewed publication or a follow-up Paradromics disclosure. The Neuralink PRIME cohort has published bit-rate numbers and specific home-computing tasks. Comparable Paradromics performance disclosures would be the direct commercial benchmark against Neuralink.
Watch whether other US invasive BCI operators pursue similar FDA-approval-letter expansions for personal-device use within their own study protocols. If Blackrock Neurotech, Synchron, or Precision Neuroscience files for an equivalent expansion, that suggests the FDA is comfortable with an approval-letter pathway for personal-device use, which shortens the path from research use to consumer-adjacent use across the category.